Letters to the Editor

An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia

Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg
Hospital Universitari i Politecnic La Fe, Valencia, Spain; CIBERONC, Instituto Carlos III, Madrid
Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster
Uniklinikum Dresden, Dresden
Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH
Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin
Hematology Department, Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcelona
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT
BoehringeaBoehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Rissr Ingelheim Pharma GmbH and Co. KG, Biberach/Riss
Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss
Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach/Riss
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
Haematologica Early view Aug 25, 2022 https://doi.org/10.3324/haematol.2022.281128